Cargando…

Metabolomic Profile in Venous Thromboembolism (VTE)

Venous thromboembolism (VTE) is a condition comprising deep venous thrombosis (DVT) and pulmonary embolism (PE). The prevalence of this disease is constantly increasing and it is also a chief reason for morbidity. Therefore, the primary prevention of VTE remains a highly important public health issu...

Descripción completa

Detalles Bibliográficos
Autores principales: Franczyk, Beata, Gluba-Brzózka, Anna, Ławiński, Janusz, Rysz-Górzyńska, Magdalena, Rysz, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400436/
https://www.ncbi.nlm.nih.gov/pubmed/34436436
http://dx.doi.org/10.3390/metabo11080495
_version_ 1783745314483601408
author Franczyk, Beata
Gluba-Brzózka, Anna
Ławiński, Janusz
Rysz-Górzyńska, Magdalena
Rysz, Jacek
author_facet Franczyk, Beata
Gluba-Brzózka, Anna
Ławiński, Janusz
Rysz-Górzyńska, Magdalena
Rysz, Jacek
author_sort Franczyk, Beata
collection PubMed
description Venous thromboembolism (VTE) is a condition comprising deep venous thrombosis (DVT) and pulmonary embolism (PE). The prevalence of this disease is constantly increasing and it is also a chief reason for morbidity. Therefore, the primary prevention of VTE remains a highly important public health issue. At present, its diagnosis generally relies on subjective clinical examination and ultrasound imaging. D-dimer is also used as a biomarker, but it is considered to be poorly specific and only moderately sensitive. There are also no reliable methods that could accurately guide the type of treatment and potentially identify patients who may benefit from more aggressive therapies without the risk of bleeding. The application of metabolomics profiling in the area of vascular diseases may become a turning point in early diagnosis and patient management. Among the most described metabolites possibly related to VTE are carnitine species, glucose, phenylalanine, 3-hydroxybutarate, lactic acid, tryptophan and some monounsaturated and polyunsaturated fatty acids. The cell response to acute PE was suggested to involve the uncoupling between glycolysis and oxidative phosphorylation. Despite technological advancement in the identification of metabolites and their alteration in thrombosis, we still do not understand the mechanisms and pathways responsible for the occurrence of observed alterations.
format Online
Article
Text
id pubmed-8400436
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84004362021-08-29 Metabolomic Profile in Venous Thromboembolism (VTE) Franczyk, Beata Gluba-Brzózka, Anna Ławiński, Janusz Rysz-Górzyńska, Magdalena Rysz, Jacek Metabolites Review Venous thromboembolism (VTE) is a condition comprising deep venous thrombosis (DVT) and pulmonary embolism (PE). The prevalence of this disease is constantly increasing and it is also a chief reason for morbidity. Therefore, the primary prevention of VTE remains a highly important public health issue. At present, its diagnosis generally relies on subjective clinical examination and ultrasound imaging. D-dimer is also used as a biomarker, but it is considered to be poorly specific and only moderately sensitive. There are also no reliable methods that could accurately guide the type of treatment and potentially identify patients who may benefit from more aggressive therapies without the risk of bleeding. The application of metabolomics profiling in the area of vascular diseases may become a turning point in early diagnosis and patient management. Among the most described metabolites possibly related to VTE are carnitine species, glucose, phenylalanine, 3-hydroxybutarate, lactic acid, tryptophan and some monounsaturated and polyunsaturated fatty acids. The cell response to acute PE was suggested to involve the uncoupling between glycolysis and oxidative phosphorylation. Despite technological advancement in the identification of metabolites and their alteration in thrombosis, we still do not understand the mechanisms and pathways responsible for the occurrence of observed alterations. MDPI 2021-07-29 /pmc/articles/PMC8400436/ /pubmed/34436436 http://dx.doi.org/10.3390/metabo11080495 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Franczyk, Beata
Gluba-Brzózka, Anna
Ławiński, Janusz
Rysz-Górzyńska, Magdalena
Rysz, Jacek
Metabolomic Profile in Venous Thromboembolism (VTE)
title Metabolomic Profile in Venous Thromboembolism (VTE)
title_full Metabolomic Profile in Venous Thromboembolism (VTE)
title_fullStr Metabolomic Profile in Venous Thromboembolism (VTE)
title_full_unstemmed Metabolomic Profile in Venous Thromboembolism (VTE)
title_short Metabolomic Profile in Venous Thromboembolism (VTE)
title_sort metabolomic profile in venous thromboembolism (vte)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400436/
https://www.ncbi.nlm.nih.gov/pubmed/34436436
http://dx.doi.org/10.3390/metabo11080495
work_keys_str_mv AT franczykbeata metabolomicprofileinvenousthromboembolismvte
AT glubabrzozkaanna metabolomicprofileinvenousthromboembolismvte
AT ławinskijanusz metabolomicprofileinvenousthromboembolismvte
AT ryszgorzynskamagdalena metabolomicprofileinvenousthromboembolismvte
AT ryszjacek metabolomicprofileinvenousthromboembolismvte